Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03903250 · ClinicalTrials.gov registry record · NA
Effects of A-GPC on Reaction Time and Cognitive Function
A NA study, sponsored by University of Mary Hardin-Baylor.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT03903250 is a NA study that has completed, run by University of Mary Hardin-Baylor. The registered enrollment target is 18 participants.
The verdict
NCT03903250, a NA study, has completed, sponsored by University of Mary Hardin-Baylor.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a randomized, double blind, crossover design study which measures the effect of alpha-glycerylphosphorylcholine (A-GPC) on reaction time and cognitive function in non-resistance trained males and females. Participants will complete baseline testing and then be randomized into one of two crossover treatments. Participants will report to the lab for five consecutive days whilst only getting a maximum of five hours of sleep per night from Monday through Thursday night. Once testing is complete on Friday, participants will receive a one week washout period then return to complete the opposite treatment.
Interventions
- DIETARY_SUPPLEMENT A-GPC
- DIETARY_SUPPLEMENT Sugar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-03-25 |
| Est. Completion | 2020-09-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03903250
The ClinicalTrials.gov registry entry for NCT03903250 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Mary Hardin-Baylor, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which A-GPC is the first listed.
NCT03903250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03903250 about?
NCT03903250 is a clinical study titled "Effects of A-GPC on Reaction Time and Cognitive Function". This is a randomized, double blind, crossover design study which measures the effect of alpha-glycerylphosphorylcholine (A-GPC) on reaction time and cognitive function in non-resistance trained males and females. Participants will complete baseline testing and then be randomized into one of two cros...
What is the current status of trial NCT03903250?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2019-03-25. Estimated completion is 2020-09-18.
What interventions are being tested in trial NCT03903250?
The interventions under investigation include: A-GPC (DIETARY_SUPPLEMENT), Sugar (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03903250?
This trial is sponsored by University of Mary Hardin-Baylor, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.